Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI might reveal hidden pancreatic risks in obesity

NCT ID NCT04007640

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study investigates whether MRI can detect early signs of pancreatic damage linked to obesity and metabolic syndrome, which are risk factors for pancreatic cancer. Researchers will compare MRI images with tissue samples from patients undergoing pancreatic surgery, as well as from healthy volunteers and obese individuals. The goal is to develop better screening tools to catch precancerous changes early.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MRI with additional sequences
What this could lead to
If successful, this could lead to better imaging tools for early detection of pancreatic cancer in people with obesity or metabolic syndrome.
What could go wrong
This is an early-stage study with a small number of participants, so results may not apply broadly. MRI findings may not perfectly match actual tissue changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

41 people

The number who actually took part.

Started

Jun 2019

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1st stage : Volunteers without history of known pancreatic disorders \- Adults * 2nd stage : Obese Volunteers * Adults with planned hepatic MRI * Obese (BMI ≥30) * 3rd stage : Patients * Adults (aged 18-65 years) with a planned pancreatic surgery for benign pancreatic lesions (IPMN, cystic lesions or neuroendocrine tumors) * Obese (BMI≥30), overweight (25≤BMI≤29.9) or non-obese patients (18.5\<BMI\<24.9) Exclusion Criteria: For volunteers without history of known pancreatic disorders (1st stage): \- Symptoms or past medical history suggesting pancreatic disorders For all participants (1st, 2nd and 3rd stages) : * Patients with contraindication to MRI (pacemaker, claustrophobia…) * Inability to undergo MRI due to weight excess * Pregnant or breastfeeding woman * Absence of free and informed consent * Non affiliation to a social security regime or CMU * Subject deprived of freedom, subject under a legal protective measure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Benign pancreatic lesions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign neoplasm of pancreas diabetes mellitus malignant pancreatic neoplasm metabolic syndrome X Obesity pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic cancer

Contacts and locations

Locations

  • Hôpital Beaujon

    Clichy, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.